This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sarepta: Second Patient Doing Well On Muscular Dystophy Drug Trial

BOTHELL, Wash. ( TheStreet) --Another kid with muscular dystrophy is showing vast improvement after treatment with Sarepta Therapeutics' (SRPT - Get Report) experimental drug eteplirsen, pushing the company shares higher in Thursday trading.

The latest anecdotal report from Sarepta's small phase II study of the Duchenne muscular dystrophy drug comes courtesy of KFVS, a local TV station in southeast Missouri. The station broadcast a news report Wednesday night on Justin Trovillion, 12, a DMD patient who appears to be responding well to treatment with the higher, 50 mg dose of eteplirsen.

Sarepta shares rose $1.73, or 14%, to $14.29 as a link to the KFVS story was passed along by investors.

The improvements observed in Trovillion's muscle strength and endurance seem to echo those of Max Leclaire, 10, of Vermont and another patient treated with the 50 mg dose of eteplirsen in Sarepta's phase II trial.

Sarepta only enrolled four boys into the 50 mg dose arm of the eteplirsen study, so it now appears as if at least 50% are demonstrating significant improvements. Sarepta announced positive, interim results from the study in July and is expected to present important follow-up data in October.

If the final eteplirsen results confirm the benefit seen at the interim analysis, Sarepta is expected to request accelerated approval for the drug from the U.S. Food and Drug Administration. Under new rules, FDA has been encouraged to accelerate the approval of life-saving drugs for diseases that have no cure. DMD certainly fits that category. The challenge for both Sarepta and FDA will be to review eteplirsen based on a small study that enrolled just 12 patients.

Sarepta needs additional cash to ramp up manufacturing of eteplirsen, which is very complicated to produce. With the stock ramping higher, speculation has centered around if and when the company will announce a new financing.

Dystrophin is a protein that plays key role in muscle function and repair. The genetic inability to make dystrophin is what causes muscular dystrophy. Eteplirsen is designed to "skip over" the section of damaged gene in DMD patients and therefore restore the gene's ability to produce partially functioning dystrophin.

GlaxoSmithKline (GSK - Get Report) is also developing a similar drug for DMD.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
GSK $45.26 0.00%
SRPT $26.22 0.00%
AAPL $132.54 0.00%
FB $80.54 0.00%
GOOG $540.11 0.00%

Markets

DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs